Intracellular Carboxyl Esterase Activity Is a Determinant of Cellular Sensitivity to the Antineoplastic Agent KW-2189 in Cell Lines Resistant to Cisplatin and CPT-11-Reference-Cited by-同舟云学术

Intracellular Carboxyl Esterase Activity Is a Determinant of Cellular Sensitivity to the Antineoplastic Agent KW-2189 in Cell Lines Resistant to Cisplatin and CPT-11

Published:1995-01 Issue:1 Volume:86 Page:124-129
ISSN:0910-5050
Container-title:Japanese Journal of Cancer Research
language:en
Short-container-title:

Author:

Ogasawara Hayato,Nishio Kazuto,Kanzawa Fumihiko,Lee Yong-Sik,Funayama Yasunori,Ohira Tatsuo,Kuraishi Yasunobu,Isogai Yukihide,Saijo Nagahiro

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1349-7006.1995.tb02997.x/fullpdf

Reference15 articles.

1. Anticellular and antitumor activity of duocarmycins, novel antitumor antibiotics;Gomi;Jpn. J. Cancer Res.,1992

2. Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors;Kobayashi;Cancer Res.,1994

3. A novel antitumor antibiotic, KW-2189 is activated by carboxyl esterase and induces DNA strand breaks in human small cell lung cancer cells;Ogasawara;Jpn. J. Cancer Res.,1994

4. Effects of KW-2189 on MOLT-3 human leukemia and HT-29 colon carcinoma cells;Arkin;Proc. Am. Assoc. Cancer Res.,1994

5. Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin;Niimi;Cancer Res.,1992

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. One-pot synthesis and enzyme-responsiveness of amphiphilic doxorubicin prodrug nanomicelles for cancer therapeutics;RSC Advances;2022

2. Antibody-Drug Conjugate PCMC1D3-Duocarmycin SA as a Novel Therapeutic Entity for Targeted Treatment of Cancers Aberrantly Expressing MET Receptor Tyrosine Kinase;Current Cancer Drug Targets;2021-12-22

3. Duocarmycin-based antibody–drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress;Drug Discovery Today;2021-08

4. How can the potential of the duocarmycins be unlocked for cancer therapy?;Drug Discovery Today;2021-02

5. A validated UPLC-MS/MS method to determine free and total irinotecan and its two metabolites in human plasma after intravenous administration of irinotecan hydrochloride liposome injection;Journal of Pharmaceutical and Biomedical Analysis;2019-06